Valuation: Cellink AB

Market Cap 167.26Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.62TCr 24Cr 66Cr 825.37Cr 63Cr 61Cr 2.65TCr P/E 2026 *
-7.36x
P/E 2027 * -13.2x
Enterprise Value 160.36Cr 16Cr 14Cr 13Cr 12Cr 23Cr 1.55TCr 23Cr 63Cr 791.32Cr 60Cr 59Cr 2.54TCr EV / Sales 2026 *
0.99x
EV / Sales 2027 * 0.89x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 51 01/09/2026
Director of Finance/CFO 56 01/03/2026
Chief Operating Officer - 07/01/2026
Director TitleAgeSince
Director/Board Member 71 18/12/2019
Director/Board Member 37 01/03/2015
Director/Board Member 51 07/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 17Cr
+0.93%+0.49%+25.38%+33.57% 24TCr
+1.08%+2.69%+8.57%+1.56% 15TCr
+2.06%+8.17%-1.31%+50.45% 15TCr
+1.64%+0.31%-55.21%-16.07% 6.19TCr
+1.15%+0.07%+15.24%+19.78% 4.91TCr
+2.30%+3.38%-17.09%-18.27% 4.88TCr
+1.41%+1.65%+24.83%+50.41% 4.81TCr
+3.96%+8.34%+3.33%+36.64% 4.79TCr
+1.08%+2.01%+31.05%+62.95% 4.26TCr
Average +1.56%+2.82%+3.86%+24.56% 9.4TCr
Weighted average by Cap. +1.51%+2.75%+7.65%+25.90%

Financials

2026 *2027 *
Net sales 162.2Cr 16Cr 14Cr 13Cr 12Cr 23Cr 1.57TCr 23Cr 64Cr 800.39Cr 61Cr 60Cr 2.57TCr 168.55Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.63TCr 24Cr 66Cr 831.72Cr 63Cr 62Cr 2.67TCr
Net income -23Cr -2.27Cr -2.03Cr -1.89Cr -1.72Cr -3.24Cr -219.71Cr -3.25Cr -8.89Cr -112.01Cr -8.52Cr -8.34Cr -359.46Cr -13Cr -1.26Cr -1.13Cr -1.05Cr -95.22L -1.8Cr -121.95Cr -1.81Cr -4.94Cr -62Cr -4.73Cr -4.63Cr -199.53Cr
Net Debt -6.9Cr -69.01L -61.63L -57.33L -52.15L -98.46L -67Cr -98.88L -2.7Cr -34Cr -2.59Cr -2.53Cr -109.26Cr -17Cr -1.66Cr -1.48Cr -1.38Cr -1.25Cr -2.37Cr -160.67Cr -2.38Cr -6.5Cr -82Cr -6.23Cr -6.1Cr -262.87Cr
Logo Cellink AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Cellink AB